Related references
Note: Only part of the references are listed.Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?
Adela Rodriguez et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Are Recently Evaluated Drugs More Likely to Receive Positive Reimbursement Recommendations in South Korea? 11-year Experience of the South Korean Positive List System
Ji Ryoun Gong et al.
CLINICAL THERAPEUTICS (2020)
Do we consider to apply the value framework of cancer drugs to clinical practice and health insurance coverage in Korea?
Do Yeun Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score
Nathan I. Cherny et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials
Ronak Saluja et al.
JAMA ONCOLOGY (2019)
Value-based medicine in oncology: the importance of perspective in the emerging value frameworks
Alessandro Goncalves Campolina
CLINICS (2018)
Re-aligning the ASCO and ESMO clinical benefit frameworks for modern cancer therapies
J. C. Del Paggio et al.
ANNALS OF ONCOLOGY (2018)
Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks
Joseph C. Del Paggio et al.
LANCET ONCOLOGY (2017)
Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs
Tanya G. K. Bentley et al.
VALUE IN HEALTH (2017)
Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center
Leslie Wilson et al.
Journal of Managed Care & Specialty Pharmacy (2017)
Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs
Daniel J. Becker et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
Utilisation of the ESMO-MCBS in practice of HTA
C. Wild et al.
ANNALS OF ONCOLOGY (2016)
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received
Lowell E. Schnipper et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials
Hemanth Kumar et al.
JAMA ONCOLOGY (2016)
Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014
Stacie B. Dusetzina
JAMA ONCOLOGY (2016)
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2015)
Are High Drug Prices for Hematologic Malignancies Justified? A Critical Analysis
Jagpreet Chhatwal et al.
CANCER (2015)
From Translation to Version Management: A History and Review of Methods for the Cultural Adaptation of the EuroQol Five-Dimensional Questionnaire
Rosalind Rabin et al.
VALUE IN HEALTH (2014)
Unintended Consequences of Expensive Cancer Therapeutics-The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity The John Conley Lecture
Tito Fojo et al.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY (2014)
Market Spiral Pricing of Cancer Drugs
Donald W. Light et al.
CANCER (2013)
Korean Guidelines for Pharmacoeconomic Evaluation (Second and Updated Version) Consensus and Compromise
SeungJin Bae et al.
PHARMACOECONOMICS (2013)
Sample size formulas for estimating intraclass correlation coefficients with precision and assurance
G. Y. Zou
STATISTICS IN MEDICINE (2012)
The Role of the US Food and Drug Administration Review Process: Clinical Trial Endpoints in Oncology
Amy E. McKee et al.
ONCOLOGIST (2010)
Share Paper
